Residual neuromuscular blockade in a real life clinical setting: Correlation with sugammadex or neostigmine administration

Minerva Anestesiologica

Volumn 82, Issue 5, 2016, Pages 550-558

  Batistaki, Chrysanthi ^a   Tentes, Panagiotis ^a   Deligiannidi, Paraskevi ^a   Karakosta, Agathi ^a   Florou, Panagiota ^a   Kostopanagiotou, Georgia ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Aneshesia; Neuromuscular blocking agents; Sugammadex

Indexed keywords

ANESTHETIC AGENT; ATROPINE; CISATRACURIUM; NEOSTIGMINE; ROCURONIUM; SUGAMMADEX; SUXAMETHONIUM; ANDROSTANE DERIVATIVE; ATRACURIUM BESILATE; GAMMA CYCLODEXTRIN DERIVATIVE; NEUROMUSCULAR BLOCKING AGENT;

ACCELEROMETRY; ADULT; ANESTHESIA LEVEL; COMORBIDITY; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GENDER; GENERAL ANESTHESIA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NEUROMUSCULAR BLOCKING; POSTOPERATIVE PERIOD; PREVALENCE; RECOVERY ROOM; RESIDUAL NEUROMUSCULAR BLOCKADE; TERTIARY CARE CENTER; TRAIN OF FOUR RATIO; ANESTHETIC RECOVERY; DELAYED EMERGENCE FROM ANESTHESIA; GREECE; MIDDLE AGED; NEUROMUSCULAR MONITORING; PROCEDURES; PROSPECTIVE STUDY;

ANDROSTANOLS; ANESTHESIA RECOVERY PERIOD; ATRACURIUM; DELAYED EMERGENCE FROM ANESTHESIA; FEMALE; GAMMA-CYCLODEXTRINS; GREECE; HUMANS; MALE; MIDDLE AGED; NEOSTIGMINE; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR BLOCKING AGENTS; NEUROMUSCULAR MONITORING; NEUROMUSCULAR NONDEPOLARIZING AGENTS; PROSPECTIVE STUDIES; SUCCINYLCHOLINE;

EID: 84971222049     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Lien CA, Kopman AF. Current recommendations for monitoring depth of neuromuscular blockade. Curr Opin Anaesthesiol 2014;27:616-22.
2. Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I. definitions, incidence and adverse physiologic effects of residual neuromuscular block. Anesth Analg 2010;111:120-8.
3. Brull SJ, Murphy GS, Residual neuromuscular block: lessons unlearned. Part Methods to reduce the risk of residual weakness. Anesth Analg 2010;111:129-40.
4. Murphy GS. Residual neuromuscular blockade: incidence, assessment and relevance in the postoperative period. Minerva Anestesiol 2006;72:97-109.
5. Claudius C, Garvey LH, Viby-Mogensen J. The undesirable effects of neuromuscular blocking drugs. Anaesthesia 2009;64(Suppl 1):10-21.
6. Della Rocca G, Pompei L. A novel approach to reversal of neuromuscular blockade. Minerva Anesthesiol 2009;75:349-51.
7. Nagelhout JJ. Reversal of neuromuscular blocking agents: current practice. AANA J 2013;(Suppl 8-11).
8. Esteves S, Martins M, Barros F, Barros F, Manuela C, Vitor P, et al. Incidence of postoperative residual neuromuscular blockade in the postanaesthesia care unit. An observational musticentre study in Portugal. Eur J Anaesthesiol 2013;30:243-9.
9. Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PAC U after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology 2005;98:1042-8.
10. Cammu G, De Witte J, De Veylder J, Byttebier G, Vandeput D, Foubert L, et al. Postoperative residual paralysis in outpatients versus inpatients. Anesth Analg 2006;102:426-9.
11. Cammu GV, Smet V, De Jongh K, Vandeput D. A prospective, observational study comparing postoperative residual curarisation and early adverse respiratory events in patients reversed with neostigmine or sugammadex or after apparent spontaneous recovery. Anesth Intesive Care 2012;40:999-1006.
12. Yip PC, Hannam JA, Cameron AJD, Campbell D. Incidence of neuromuscular blockade in a postanaesthetic care unit. Anaesth Intensive Care 2010;38:91-5.
13. Ledowski T, Falke L, Johnston F, Gillies E, Greenaway M, De Mel A, et al. retrospective investigation of prostoperative outcome after reversal of residual neuromuscular blockade. Sugammadex, neostigmine or no reversal. Eur J Anaesthesiol 2013;30:1-7.
14. Butterly A, Bittner EA, George E, Sandberg WS, Eikermann M, Schmidt U. Postoperative residual curarization from intermediate-acting neuromuscular blocking agents delays recovery room discharge. Br J Anaesth 2010;105:304-9.
15. Berg H, Roed J, Viby-Mogensen J, Mortensen CR, Engbaek J, Skovgaard LTLT, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospectve, randomized and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 1997;41:1095-103.
16. Murphy GS, Szokol JW, Marymont JH, Vender JS, Avram MJ, Rosengart TK, et al. Recovery of neuromuscular function after cardiac surgery: pancuronium versus rocuronium. Anesth Analg 2003;96:1301-7.
17. Murphy GS, Szokol JW, Franklin M, Marymont JH, Avram MJ, Vender JS. Postanesthesia care unit recovery times and neuromuscular blocking drugs: A prospective study of orthopedic surgical patients randomized to receive pancuronium or rocuronium. Anesth Analg 2004;98:193-200.
18. Naguib M, Kopman AF, Ensor JE. Neuromuscular monitoring and postoperative residual curarisation: A meta-analysis. Br J Anaesth 2007;98:302-16.
19. Amorim P, Lagarto F, Gomes B, Esteves S, Bismarck J, Rodrigues N, et al. Neostigmine vs sugammadex: observational cohort study comparing the quality of recovery using the Postoperative Quaity Recovery Scale. Acta Anaesthesiol Scand 2014;58:1101-10.
20. Vannucci A. Sugammadex can be part of the solution. Let's not make it part of the problem! Minerva Anestesiol 2013;79:587-9.
21. Della Rocca G, Di Marco P, Beretta L, De Gauidio AR, Ori C, MastronarDi P. Do we need sugammadex at the end of a general anesthesia to reverse the action of neuromuscular blocking agents? Position Paper on Sugammadex use. Minerva Anestesiol 2013;79:661-6.
22. Dahl V, Pendeville PE, Hollmann MW, Heier T, Abels EA, Blobner M. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Eur J Anaesthesiol. 2009;26:874-84.
23. Cammu G, Coart D, De Graeve K, Beelen R. Reversal of rocuronium induced neuromuscular block with sugammadex in heart failure patients: A prospective observational study. Acta Anaesthesiol Belg. 2012;63:69-73.
24. Gómez-Ríos MA, López. LR. Use of combination of rocuronium and sugammadex in heart transplant recipients. Anaesth Intensive Care 2012;40:903-4.
25. Batistaki C, Christodoulaki K, Nakou M, Kostopanagiotou G. General anaesthesia in a recent heart transpant recipient for endovascuar aortic aneurysm repair. Anaesth Intensive Care 2013;41:270-1.
26. De Boer HD, Shields MO, Booij LH. Reversal of neuromuscular blockade with sugammadex in patients with myasthenia gravis: A case series of 21 patients and review of the literature. Eur J Anaesthesiol 2014;31:715-21.
27. Kaan N, Kocaturk O, Kurt I, Cicek H. The incidence of residual neuromuscular blockade associated with single dose of intermediate-acting neuromuscular blocking drugs. Midde East J Anaesthesiol 2012;21:535-41.
28. Adamus M, Hrabalek, Wanek T, Gabrhelik T, Zapetalova J. Infuence of age and gender on the pharmacodynamic parameters of rocuronium during total intravenous anesthesia. Biomed Pap Med Fac Univ Paacky Olomouc Chech Repub 2011;155:347-53.
29. DeBoer HD, Booij LH. Why are we using pulse oximetry but not neuromuscular monitoring routinely: the real world scenario. Anesth Analg 2014;118:690.
30. Kotake Y, Ochiai R, Suzuki T, Ogawa S, Takagi S, Ozaki M, et al. Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular blockade. Anesth Analg 2013;117:345-5.